Superior and Sustained Performance: Arthramid achieves 80-85% efficacy across multiple peer-reviewed studies Long-lasting Results: Clinical studies demonstrate sustained efficacy up to 2 years post-treatment Evidence-Based Efficacy: Double-blinded controlled studies confirm Arthramid outperforms triamcinolone steroid and hyaluronic acid Proven Safety Profile: Histopathology studies confirm successful joint integration and biocompatibility Robust Research Foundation: Results validated across six independent peer-reviewed studies spanning multiple research teams and geographical locations Unlike many joint treatments on the market, Arthramid is backed by a growing body of robust, real-world research, not just anecdotal outcomes
I've never taken 'expiry' / 'best before' / 'use by' dates totally to be adhered to, except in certain circumstances
Get more energy, less aging, and faster recovery with NAD+ transdermal patches
IOP Publishing, p 012149 (2021) Maddali, H., Miles, C.E., Kohn, J., OCarroll, D.M.: Optical biosensors for virus detection: prospects for SARS-CoV-2/COVID-19
